348 related articles for article (PubMed ID: 29983085)
1. Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients.
Hu RM; Tester DJ; Li R; Sun T; Peterson BZ; Ackerman MJ; Makielski JC; Tan BH
Channels (Austin); 2018; 12(1):176-186. PubMed ID: 29983085
[TBL] [Abstract][Full Text] [Related]
2. Complex interactions in a novel SCN5A compound mutation associated with long QT and Brugada syndrome: Implications for Na+ channel blocking pharmacotherapy for de novo conduction disease.
Liu J; Bayer JD; Aschar-Sobbi R; Wauchop M; Spears D; Gollob M; Vigmond EJ; Tsushima R; Backx PH; Chauhan VS
PLoS One; 2018; 13(5):e0197273. PubMed ID: 29791480
[TBL] [Abstract][Full Text] [Related]
3. A distinct molecular mechanism by which phenytoin rescues a novel long QT 3 variant.
Gando I; Campana C; Tan RB; Cecchin F; Sobie EA; Coetzee WA
J Mol Cell Cardiol; 2020 Jul; 144():1-11. PubMed ID: 32339567
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of chronic mexiletine treatment in a human model of SCN5A overlap syndrome.
Nasilli G; Yiangou L; Palandri C; Cerbai E; Davis RP; Verkerk AO; Casini S; Remme CA
Europace; 2023 Jun; 25(6):. PubMed ID: 37369559
[TBL] [Abstract][Full Text] [Related]
5. Arrhythmogenic Biophysical Phenotype for SCN5A Mutation S1787N Depends upon Splice Variant Background and Intracellular Acidosis.
Hu RM; Tan BH; Tester DJ; Song C; He Y; Dovat S; Peterson BZ; Ackerman MJ; Makielski JC
PLoS One; 2015; 10(4):e0124921. PubMed ID: 25923670
[TBL] [Abstract][Full Text] [Related]
6. A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine.
Valdivia CR; Ackerman MJ; Tester DJ; Wada T; McCormack J; Ye B; Makielski JC
Cardiovasc Res; 2002 Aug; 55(2):279-89. PubMed ID: 12123767
[TBL] [Abstract][Full Text] [Related]
7. Lidocaine attenuation testing: An in vivo investigation of putative LQT3-associated variants in the SCN5A-encoded sodium channel.
Anderson HN; Bos JM; Kapplinger JD; Meskill JM; Ye D; Ackerman MJ
Heart Rhythm; 2017 Aug; 14(8):1173-1179. PubMed ID: 28412158
[TBL] [Abstract][Full Text] [Related]
8. The Citrus Flavonoid Hesperetin Has an Inadequate Anti-Arrhythmic Profile in the ΔKPQ Na
Alvarez-Collazo J; López-Requena A; Alvarez JL; Talavera K
Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32599724
[TBL] [Abstract][Full Text] [Related]
9. Predicting Patient Response to the Antiarrhythmic Mexiletine Based on Genetic Variation.
Zhu W; Mazzanti A; Voelker TL; Hou P; Moreno JD; Angsutararux P; Naegle KM; Priori SG; Silva JR
Circ Res; 2019 Feb; 124(4):539-552. PubMed ID: 30566038
[TBL] [Abstract][Full Text] [Related]
10. Functional characterization and identification of a therapeutic for a novel SCN5A-F1760C variant causing type 3 long QT syndrome refractory to all guideline-directed therapies.
Stutzman MJ; Gao X; Kim M; Ye D; Zhou W; Tester DJ; Giudicessi JR; Shannon K; Ackerman MJ
Heart Rhythm; 2023 May; 20(5):709-717. PubMed ID: 36731785
[TBL] [Abstract][Full Text] [Related]
11. Further Insights in the Most Common SCN5A Mutation Causing Overlapping Phenotype of Long QT Syndrome, Brugada Syndrome, and Conduction Defect.
Veltmann C; Barajas-Martinez H; Wolpert C; Borggrefe M; Schimpf R; Pfeiffer R; Cáceres G; Burashnikov E; Antzelevitch C; Hu D
J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27381756
[TBL] [Abstract][Full Text] [Related]
12. Trafficking defects and gating abnormalities of a novel SCN5A mutation question gene-specific therapy in long QT syndrome type 3.
Ruan Y; Denegri M; Liu N; Bachetti T; Seregni M; Morotti S; Severi S; Napolitano C; Priori SG
Circ Res; 2010 Apr; 106(8):1374-83. PubMed ID: 20339117
[TBL] [Abstract][Full Text] [Related]
13. Reduced current density, partially rescued by mexiletine, and depolarizing shift in activation of SCN5A W374G channels as a cause of severe form of Brugada syndrome.
Nakajima T; Dharmawan T; Kawabata-Iwakawa R; Tamura S; Hasegawa H; Kobari T; Ota M; Tange S; Nishiyama M; Kaneko Y; Kurabayashi M
Ann Noninvasive Electrocardiol; 2021 May; 26(3):e12828. PubMed ID: 33463855
[TBL] [Abstract][Full Text] [Related]
14. Anti-arrhythmic potential of the late sodium current inhibitor GS-458967 in murine Scn5a-1798insD+/- and human SCN5A-1795insD+/- iPSC-derived cardiomyocytes.
Portero V; Casini S; Hoekstra M; Verkerk AO; Mengarelli I; Belardinelli L; Rajamani S; Wilde AAM; Bezzina CR; Veldkamp MW; Remme CA
Cardiovasc Res; 2017 Jun; 113(7):829-838. PubMed ID: 28430892
[TBL] [Abstract][Full Text] [Related]
15. Long-term flecainide therapy in type 3 long QT syndrome.
Chorin E; Taub R; Medina A; Flint N; Viskin S; Benhorin J
Europace; 2018 Feb; 20(2):370-376. PubMed ID: 28339995
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of Ranolazine on E1784K is altered by temperature and calcium.
Abdelsayed M; Ruprai M; Ruben PC
Sci Rep; 2018 Feb; 8(1):3643. PubMed ID: 29483621
[TBL] [Abstract][Full Text] [Related]
17. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients.
Ruan Y; Liu N; Bloise R; Napolitano C; Priori SG
Circulation; 2007 Sep; 116(10):1137-44. PubMed ID: 17698727
[TBL] [Abstract][Full Text] [Related]
18. The biophysical characterization of the first SCN5A mutation R1512W identified in Chinese sudden unexplained nocturnal death syndrome.
Zheng J; Zhou F; Su T; Huang L; Wu Y; Yin K; Wu Q; Tang S; Makielski JC; Cheng J
Medicine (Baltimore); 2016 Jun; 95(23):e3836. PubMed ID: 27281089
[TBL] [Abstract][Full Text] [Related]
19. Multiple mechanisms underlie increased cardiac late sodium current.
Kroncke BM; Yang T; Roden DM
Heart Rhythm; 2019 Jul; 16(7):1091-1097. PubMed ID: 30677491
[TBL] [Abstract][Full Text] [Related]
20. Digenic inheritance novel mutations in SCN5a and SNTA1 increase late I(Na) contributing to LQT syndrome.
Hu RM; Tan BH; Orland KM; Valdivia CR; Peterson A; Pu J; Makielski JC
Am J Physiol Heart Circ Physiol; 2013 Apr; 304(7):H994-H1001. PubMed ID: 23376825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
